CD274 and neoplasm: Once the CRISPR/Cas13a system located the tumor cell, played a role in targeting, disrupted the programmed PD-L1 through gene editing, and achieved the controlled release, thereby leading to the safe and efficient activation of T-cell-mediated immunotherapy [235].